| You
are here: Home: BCU 1|2003: Dr.
Larry Norton, MD: Select Publications
Select Publications
Dose-dense chemotherapy regimens
Citron M et al. Superiority of dose-dense (DD) over conventional
scheduling (CS) and equivalence of sequential (SC) vs. combination
adjuvant chemotherapy (CC) for node-positive breast cancer (CALBG
9741, INT C9741). Breast Cancer Res Treat 2002; Abstract
15.
De Giorgi U et al. High-dose epirubicin, preceded by dexrazoxane,
given in combination with paclitaxel and filgrastim provide a safe
and effective mobilization regimen to support three courses of high-dose
dense chemotherapy in patients with stage II-III breast cancer.
Proc ASCO 2002; Abstract
1680.
Eggemann H et al. Sequential dose-dense epirubicin/paclitaxel
(E-T) with G-CSF support compared to standard EC – T (epirubicin/cyclophosphamide
followed by paclitaxel) for patients with operable breast cancer
and 1-3 positive lymph nodes-first toxicity analysis. Breast
Cancer Res Treat 2002; Abstract
646.
Ellis GK et al. Dose-dense anthracycline-based chemotherapy
for node-positive breast cancer. J Clin Oncol 2002;20(17):3637-43.
Abstract
Emens LA et al. A phase I toxicity and feasibility trial
of sequential dose-dense induction chemotherapy with doxorubicin,
paclitaxel, and 5-fluorouracil followed by high dose consolidation
for high-risk primary breast cancer. Breast Cancer Res
Treat 2002;76(2):145-56. Abstract
Euler U et al. Dose and time intensified epirubicin/cyclophosphamide
(EC) as preoperative treatment in locally advanced breast cancer.
Breast Cancer Res Treat 2002; Abstract
154.
Fornier MN et al. Doxorubicin followed by sequential paclitaxel
and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide:
5-year results of a phase II randomized trial of adjuvant dose-dense
chemotherapy for women with node-positive breast carcinoma.
Clin Cancer Res 2001;7(12):3934-41. Abstract
Fountzilas G et al. Dose-dense sequential chemotherapy
with epirubicin and paclitaxel versus the combination, as first-line
chemotherapy, in advanced breast cancer: A randomized study conducted
by the Hellenic Cooperative Oncology Group. J Clin Oncol
2001;19(8):2232-9. Abstract
Jackisch C et al. Primary endpoint analysis of the Geparduo-study
- Preoperative chemotherapy (PCT) comparing dose-dense versus sequential
adriamycin/docetaxel combination in operable breast cancer (T2-3,
N0-2,M0). Breast Cancer Res Treat 2002; Abstract
152.
Jackisch C et al. Dose-dense biweekly doxorubicin/docetaxel
versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel
in operable breast cancer: Second interim analysis. Clin
Breast Cancer 2002;3(4):276-80. Abstract
Norton L. Theoretical concepts and the emerging role of
taxanes in adjuvant therapy. Oncologist 2001;6 Suppl 3:30-5.
Abstract
Paciucci PAet al. Neo-adjuvant therapy with dose-dense
docetaxel (DTX) plus short-term G-CSF support for locally advanced
breast cancer (LABC). Proc ASCO 2002; Abstract
1943.
Razis E et al. Dose-dense sequential chemotherapy with
epirubicin and paclitaxel in advanced breast cancer. Cancer
Invest 2001;19(2):137-44. Abstract
Rodriguez CA et al. Dose-dense docetaxel and mitoxantrone
as first line chemotherapy for metastatic breast cancer (MBC).
Proc ASCO 2002; Abstract
1938.
Untch M et al. Dose-dense sequential epirubicin-paclitaxel
as preoperative treatment of breast cancer: Results of a randomised
AGO study. Proc ASCO 2002;
Abstract 133.
van Rossum CK et al. Dose intensification of epirubicin
and paclitaxel with G-CSF support for patients with metastatic breast
cancer: A randomized phase II study of dose-dense and dose-escalated
chemotherapy. Proc ASCO 2002; Abstract
2040.
von Minckwitz G et al. Dose-dense versus sequential adriamcycin
/ docetaxel combination as preoperative chemotherapy (pCHT) in operable
breast cancer (T2-3, N0-2,M0) - Primary endpoint analysis of the
GEPARDUO-study. Proc ASCO 2002; Abstract
168.
Hematopoetic growth factors
Anderlini P, Champlin R. Use of filgrastim for stem cell
mobilisation and transplantation in high-dose cancer chemotherapy.
Drugs 2002;62(Suppl 1):79-88. Abstract
Crawford J. Pegfilgrastim administered once per cycle
reduces incidence of chemotherapy-induced neutropenia.
Drugs 2002;62(Suppl 1):89-98. Abstract
Curran MP, Goa KL. Pegfilgrastim. Drugs 2002;62(8):1207-13;
discussion 1214-5. Abstract
Ellis GK et al. Dose-dense anthracycline-based chemotherapy
for node-positive breast cancer. J Clin Oncol 2002;20(17):3637-43.
Abstract
Frasci G. Treatment of breast cancer with chemotherapy
in combination with filgrastim: Approaches to improving therapeutic
outcome. Drugs 2002;62 Suppl 1:17-31. Abstract
Holmes FAet al. Blinded, randomized, multicenter study
to evaluate single administration pegfilgrastim once per cycle versus
daily filgrastim as an adjunct to chemotherapy in patients with
high-risk stage II or stage III/IV breast cancer. J Clin
Oncol 2002;20(3):727-31. Abstract
Holmes FAet al. Comparable efficacy and safety profiles
of once-per-cycle pegfilgrastim and daily injection filgrastim in
chemotherapy-induced neutropenia: A multicenter dose-finding study
in women with breast cancer. Ann Oncol 2002;13(6):903-9.
Abstract
Molineux G. Pegylation: engineering improved pharmaceuticals
for enhanced therapy. Cancer Treat Rev 2002;28(Suppl A):13-6.
Abstract
Nabholtz JM et al. Phase III Trial Comparing Granulocyte
Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic
Complications in Breast Cancer Patients Treated with Docetaxel/
Doxorubicin/Cyclophosphamide: Results of the BCIRG 004 Trial. Clin
Breast Cancer 2002;3(4):268-75. Abstract
Shogan JE et al. A single dose of pegfilgrastim reduces
the incidence of febrile neutropenia in various risk strata compared
with daily filgrastim following myelosuppressive chemotherapy.
Breast Cancer Res Treat 2002; Abstract
536.
Shogan JE et al. Pegfilgrastim shows safety and efficacy
similar to filgrastim in elderly patients with breast cancer.
Proc ASCO 2002; Abstract
260.
Siena S et al. A single dose of pegfilgrastim per chemotherapy
cycle allows most patients to receive an average relative dose intensity
(ARDI) = 85%. Breast Cancer Res Treat 2002; Abstract
535.
Valley AW. New treatment options for managing chemotherapy-induced
neutropenia. Am J Health Syst Pharm 2002;59(15 Suppl 4):S11-7.
Abstract
|
